How to Take Pralsetinib

Please take pralsetinib strictly in accordance with the instructions of medical professionals.

How to Take Pralsetinib

Take the medication once daily, with the dosage following the doctor’s advice.

Administer on an empty stomach. Do not eat anything for at least 2 hours before and 1 hour after taking the drug.

Do not adjust the dosage or discontinue the medication without the permission of medical staff.

If adverse reactions occur after medication, medical professionals may adjust the dosage, suspend the treatment, or permanently terminate pralsetinib therapy based on the specific conditions.

If you miss a dose, take the missed dose as soon as possible on the same day. Resume your regular dosing schedule on the following day.

If vomiting occurs after taking the medication, do not take an extra dose. Simply continue with the next scheduled dose on the following day.

Important but Uncommon Side Effects of Pralsetinib

Pulmonary Disorders

Patients may develop pulmonary inflammation (known as pneumonitis) or interstitial lung disease that can lead to lung scarring during treatment. Immediately notify your oncology care team if you experience any new or worsening symptoms, including shortness of breath, difficulty breathing, cough, or fever.

Bleeding

This medication may cause bleeding events, also referred to as severe hemorrhage. Contact your healthcare provider immediately if you notice any signs of bleeding, such as bright red or coffee-ground-like vomit, red or black tarry stools, coughing up blood, pink or brown urine, increased bruising, nosebleeds, drowsiness, headache, or slurred speech.

Wound Healing Impairment

Pralsetinib may result in delayed or incomplete wound healing, for example, non-healing or dehiscence of surgical incisions.

Always inform the surgical team that you are taking pralsetinib.

Notify your oncology team in advance if you plan to undergo any surgical procedure.

It is recommended to discontinue this medication at least 5 days prior to any surgery.

In addition, do not initiate or resume pralsetinib treatment for at least 2 weeks after major surgery, and only after all surgical incisions have fully healed.

Report to your medical team promptly if your surgical wound fails to heal or shows signs of infection (redness, swelling, warmth).

Tumor Lysis Syndrome (TLS)

Patients with a large tumor burden before treatment are at risk of developing tumor lysis syndrome. This condition occurs when cancer cells are destroyed rapidly, releasing their intracellular contents faster than the body can eliminate them.

You may be prescribed medications (e.g., allopurinol) and intravenous fluids to help prevent TLS.

Immediately notify your oncology team if you experience nausea, vomiting, diarrhea, or become lethargic (drowsy, sluggish).

TLS can affect kidney function. Your healthcare provider will monitor your renal function through blood tests.

Contact your provider right away if you have decreased urine output or no urine at all.

What Is the Prescribed Use of Pralsetinib?

Pralsetinib is indicated for the treatment of adults with specific types of non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

It is also used to treat adults and pediatric patients aged 12 years and older with specific types of thyroid cancer that has progressed or metastasized to other body sites.

Additionally, pralsetinib is indicated for adults and pediatric patients aged 12 years and older with specific types of thyroid cancer that is progressive or metastatic and unresponsive to radioactive iodine therapy.

Mechanism of Action

Pralsetinib belongs to a class of medications called kinase inhibitors. Its mechanism of action involves blocking the activity of a specific naturally occurring substance, which is potentially essential for the proliferation of cancer cells.